- RIS(for EndNote,Reference Manager,ProCite)
- Citation Only
- Citation and Abstract
No impact of filaggrin deficiency on the efficacy of epicutaneous immunotherapy in a murine model
1 DBV Technologies, Montrouge, France
2 Université Paris Descartes-Hôpital Necker-Enfants Malades, Paris, France
Received: , Accepted: , Published:
2. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. (2006) Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 38: 441-446.
6. Kawasaki H, Nagao K, Kubo A, et al. (2012) Altered stratum corneum barrier and enhanced percutaneous immune responses in filaggrin-null mice. J Allergy Clin Immunol 129: 1538-1546.
7. Dupont C, Kalach N, Soulaines P, et al (2010) Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol 125: 1165-1167.
8. Mondoulet L, Dioszeghy V, Larcher T, et al. (2012) Epicutaneous immunotherapy (EPIT) blocks the allergic esophago-gastro-enteropathy induced by sustained oral exposure to peanuts in sensitized mice. PLoS One 7: e31967.
9. Dioszeghy V, Mondoulet L, Dhelft V, et al. (2011) Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact sSkin and downregulates the allergen-specific response in sensitized mice. J Immunol 186: 5629-5637.
10. Mondoulet L, Dioszeghy V, Ligouis M, et al. (2010) Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy 40: 659-667.
12. Mondoulet L, Dioszeghy V, Puteaux E, et al. (2012) Intact skin and not stripped skin is crucial for the safety and efficacy of peanut epicutaneous immunotherapy (EPIT) in mice. Clin Transl Allergy 2: 22-34.
13. Jones SM, Agbotounou WK, Fleischer DM, et al. (2016) Safety of epicutaneous immunotherapy for the treatment of peanut allergy: A phase 1 study using the Viaskin patch. J Allergy Clin Immunol 137: 1258-1261.
14. Sampson HA, Agbotounou W, Thebaut C, et al. (2015) Epicutaneous immunotherapy (EPIT) is effective and safe to treat peanut allergy: a multi-national double-blind placebo-controlled randomized phase IIb trial. J Allergy Clin Immunol 135: AB390.
15. Presland RB, Boggess D, Lewis SP, et al. (2000) Loss of normal profilaggrin and filaggrin in flaky tail (ft/ft) mice: an animal model for the filaggrin-deficient skin disease ichthyosis vulgaris. J Invest Dermatol 115: 1072-1081.
16. Stout TE, McFarland T, Mitchell JC, et al. (2014) Recombinant filaggrin is internalized and processed to correct filaggrin deficiency. J Invest Dermatol 134: 423-429.
18. Sasaki T, Shiohama A, Kubo A, et al. (2013) A homozygous nonsense mutation in the gene for Tmem79, a component for the lamellar granule secretory system, produces spontaneous eczema in an experimental model of atopic dermatitis. J Allergy Clin Immunol 132: 1111-1120.
21. Moniaga CS, Egawa G, Kawasaki H (2010) Flaky tail mouse denotes human atopic dermatitis in the steady state and by topical application with Dermatophagoides pteronyssinus extract. Am J Pathol 176: 2385-2393.
23. Kawasaki H, Nagao K, Kubo A, et al. (2012) Altered stratum corneum barrier and enhanced percutaneous immune responses in filaggrin-null mice. J Allergy Clin Immunol 129: 1538-1546.
24. Oyoshi MK, Murphy GF, Geha RS (2009) Filaggrin-deficient mice exhibit TH17-dominated skin inflammation and permissiveness to epicutaneous sensitization with protein antigen. J Allergy Clin Immunol 124: 485-493.
25. Spergel JM, Mizoguchi E, Brewer JP, et al. (1998) Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest 101: 1614-1622.
Copyright Info: © 2017, Lucie Mondoulet, et al., licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)